AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

BLCO · NYSE · Medical - Instruments & Supplies

Bausch + Lomb (BLCO)

Makes contact lenses, eye-care products, ophthalmic medicines, and surgical tools.

$17.04

vs last close−0.29 (−1.65%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	1,007	1,173	1,099	1,216	1,196	1,280	1,137	1,278	1,281	1,405	1,244	1,389
Cost of revenue	392	461	424	483	464	501	549	592	578	589	540	568
Gross profit	615	712	675	733	732	779	588	686	703	816	704	821
	575	663	669	707	689	692	649	675	623	658	645	738
Research & development	82	80	82	84	84	93	86	96	95	94	101	114
Selling, general & administrative	418	483	504	535	511	532	563	579	528	564	544	588
Other expenses	75	100	83	88	94	67	0	0	0	0	0	36
Operating income	40	49	6	26	43	87	−61	11	80	158	59	83
	−75	−106	−96	−102	−101	−97	−119	−158	−83	−145	−123	−94
Interest income	4	3	3	3	4	5	3	3	3	3	4	4
Interest expense	76	99	99	102	100	98	97	131	103	100	100	93
Other non-operating income	−1	7	−3	−14	1	−1	22	27	−20	45	23	1
Income before tax	−35	−57	−90	−76	−58	−10	−180	−147	−3	13	−64	−11
Income tax expense	45	−6	73	72	−66	−8	31	−89	22	71	6	−1
Net income from continuing operations	−80	−51	−163	−148	8	−2	−211	−58	−25	−58	−70	−10
Net income	−84	−54	−167	−151	4	−3	−212	−62	−28	−58	−71	−14
EPS, basic	−$0.24	−$0.15	−$0.48	−$0.43	$0.01	−$0.01	−$0.60	−$0.18	−$0.08	−$0.16	−$0.20	−$0.04
EPS, diluted	−$0.24	−$0.15	−$0.48	−$0.43	$0.01	−$0.01	−$0.60	−$0.18	−$0.08	−$0.16	−$0.20	−$0.04
Weighted average shares, basic	351	351	351	352	352	352	353	354	354	354	355	357
Weighted average shares, diluted	351	351	351	352	354	352	353	354	354	354	355	357
EBITDA	123	158	119	150	152	194	23	91	209	212	137	184
Depreciation & amortization	82	116	110	110	110	106	106	107	109	99	101	102
EBIT	41	42	9	40	42	88	−83	−16	100	113	36	82